Drug intelligence / Profile preview

hPLTs-04

Development stage: Preclinical
Lead developer: HemaCell Biotechnology
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

hPLTs-04 is an ex vivo hematopoietic stem/progenitor cell (HSPC)-derived platelet cell therapy being developed by HemaCell Therapeutics (Xue Ji Bio) for the treatment of thrombocytopenia. The therapy utilizes a proprietary platform to differentiate HSPCs into mature, functional platelets in a controlled environment. Once administered via transfusion, these platelets are intended to restore systemic platelet counts and normal hemostatic function in patients suffering from low platelet levels. hPLTs-04 is specifically characterized as an O-type product to enhance its potential for universal or broad-spectrum compatibility. The program is currently in the preclinical stage of development.

Other names: hPLTs-04 (O-type)

Beyond the preview

Go deeper on hPLTs-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hPLTs-04.

Explore the full profile